# Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

> **NCT01836029** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 195 (actual)

## Conditions studied

- Carcinoma, Squamous Cell of Head and Neck

## Interventions

- **DRUG:** VTX-2337
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** 5-fluorouracil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01836029
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-14
- **Primary completion:** 2016-04-13
- **Final completion:** 2016-09-19
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2019-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01836029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01836029, "Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01836029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*